A 30-year old black woman presented with gradual onset of weakness of the legs associated with burning sensation in the feet for two months. She had been using two hydroquinonebased skin bleaching creams (MGC by M. G. C. International, MEKAKO by Anglo Fabrics I30LTON Ltd) for about four years. Her BP was 80140mm Hg supine with un-recordable diastolic pressure on standing. She had decreased power (Grade 315), loss of deep tendon reflexes and impairment of deep sensation in the lower limbs. A complete blood count, urinalysis, serum electrolytes, serum creatinine and uric acid were all normal. Oral GTT, VDRL and brucella tests were negative. Chest and abdominal radiographs did not show any abnormalities. A diagnosis of peripheral neuropathy with autonomic neuropathy possibly due to hydroquinone toxicity was made and she was advised to stop using hydroquinone based skin bleaching creams. Four months later she was asymptomatic, her BP was 1201 80mmHg supine and standing, and neurological examination was normal. The case raises the question of whether hydroquinone based skin bleaching creams could be a cause of peripheral neuropathy and underscores the need for research on hydroquinone based skin bleaching creams and neuropathy particularly in black women involved in the sale and/or use of skin bleaching creams.
INTRODUCTION
Hydroquinone (benzene-] ,4-diol) is one of the most effective inhibitors of melanogenesis and is widely used for the treatment of melanosis and other hyper-pigmentary disorders(1). It is also used in many skin bleaching creams and lotions. Hydroquinone and the related quinoline derivatives are however known to be toxic. Between 1956 and 1970, clioquinol (5-chloro-7-iodo-8-quinolinol ) was reported to have caused an epidemic of sub-acute myelooptico neuropathy (SMON) in more than 10,000 people in Japan(2). Toxicity of clioquinol and other halogenated hydroquinolines was also reported in other countries(3-6). There followed widespread reaction resulting in litigation in Japan, Switzerland and Sweden and calls for the withdrawal of the drugs (7, 8) .
The mechanism by which hydroquinolines and hydroquinone cause neuropathy is not well understood. Clioquinol treated dogs developed dysymmetric leg movements ;~ccompanied by failure to support body weight in the hind quarters, but similar forelimb involvement occurred in severely affected dogs. Neurological lesions were demonstrated in the rostra1 dorsal funiculus and distal aspects of the optic nerve fibres, with minimal to mild degenerative changes in the distal aspects of the corticospinal and spinocerebellar tracts of the dogs(9). A recent study suggests that clioquinol combines with zinc to form a potent mitochondria1 toxin and that it is the clioquinol-zinc chelate which may have been the ultimate toxin in SMON(l0).
CASE REPORT
A 30-yearold black woman and retailer ofcosmetic products was seen in July 1999 complaining of gradual onset of weakness of the legs associated with burning sensation in the feet for two months. She walked withgreat difficulty andonly whensupported. She did not have fever, cough or weight loss. She denied history of alcohol ingestion or medication prior to the onset of her illness. She had been on treatment with vitamin B connplex, neurorubin, folic acid, and analgesics for about one month but with no response. A review of her cosmetics revealed that she had been using two hydroquinone based skin bleaching creams (MEKAKO, MGC) for about four years. She applied MEK.AK0 cream to the face and MGC lotion to the rest of the body twice daily. Physical examination revealed a young woman in good nutritional state and with a very light skin complexion (of the whole body. Her BP was 80140mmHg supine with un-recordable diastolic pressure on standing. As the BP was being taken, she experienced severe pain and sweating in the right forearm. She had decreased power (Grade 3 1 3 , loss of deep tendon reflexes and impairment of deep sensation in the lower limbs. A complete blood count, urinalysis, serum electrolytes, serum creatinine and uric acid were all normal. Oral GTT, VDRL and brucella tests were negative. Chest and abdominal radiographs did not show any abnormalities. It was not possible to do a lumbar puncture, EMG or HIV serology. She was thought to have peripheral Unlike the SMON patients, our patient improved on neuropathy with autonomic neuropathy 1~0sslhly due to withdrawal of hydroquinone based creams. However, hydroquinone toxicity. She was advised to contlnue taking the since the fclllow up was short, the improvement vitamins and analgesics but to stop using hydroquinone based could have a temporary remiss,on is also a skin bleaching creams.
feature of !-,MON. The ev'dence that hydroquinone was associated with RESULTS peripheral rieuropathy in our patient is circumstantial, and Four months later she was asymptomatic except for slight paraesthesia over the medial aspect ofthe feet. Shc was able to walk well without support. Hcr BP was 1201 80mmHg supine and standing. She no lon2cr experienced pain and sweating in the rrghtforearm JS the BP was being taken. Neurologrcal cxamination was norliial. She denied history of change in medication.
DISCUSSION
The patient presented with ;hroriic. symmetric sensorimotor polyneuropathy and autononiic neuropathy. Diabetes mellitus was considered s ncc it is the most common cause of diqtal symmetric polyncuropathy(1 1). However, the patient did not have the typ~cal syrnptoms of diabetes nlellitus ancl oral GTT was norrn~~l. Other chronic metabolic diseases including hepatitis arld renal disease were also considcrccl and excludcd. It wa, not possible to do HIV serology on the patient. Howcvc~.. she did not havc clinical stigmata sugscstive of underlyir~i! HIV infection. Peripheral neuropathy has been repol-tcd in 44% of HIV infected individuals. Distal symmetric polyneuropathy occurs in twency two percent ofall cascs o HIV peripheral neuropathy(l2).
We were alerted to the possibiliiy 01' hydroquinonc neuropathy by the very light shin conlplexion of the paticnt and the finding of hydroquin1)nc-based skit] bleaching crearns among her cosrnetlcs Hydroquinone neuropathy could have arisen bccause [he patlent was using two hydroquinone based creanls nl the same time; she applied thlc creams over her whole hody twice daily contrary to the instructions on the p;ic kap Ing to apply the creams only to a small area; and she hacl been using the creams for aperiod of about four years. Finally, the paticnt improved when she stopped uslng thc hydroquinonebased skin bleaching creams.
Similar to the SMON patient,, o u~ paticrlt was a young female and presented with ilnp2.1rment of deep sensation, weakness in the lowel-lirrlbs, and autonomic neuropathy(l3). However, in conlr.ast to the SMON patients, our patient's illness was chrl.)nic. and she did not have abdominal symptoms preceding neurological symptoms nor visual or mental impail-ment. Whereas SMONpatients had used clioquinol cr other halogenated hydroquinolines, our patient used hydroquinone based creams. The route of administration was oral in the SMON patients while it was topil:al In our patient.
. .
it is not poslible to exclude the role of other factors in the aetiology aild progression of her peripheral neuropathy. This case tlocs however raise the question of whether hydroquinorie-based skin bleaching creams could be a cause of pe.xpheral neuropathy. Black women especially those ~nvoll cd in the sale of skin bleaching creams may be at greater I ~s k of exposure to hydroquinone-based skin bleaching -reams because of the popularity of skin bleaching and easy access to skin bleaching creams(l4). The proble~n may be compounded further in countries such as Uganda where regulatory measures for the sale and use ofIi;idroquinone-based skin bleaching creams are inadequate The case underscores the need for research on hydroquincr~e-based skin bleaching creams and neuropathy particularl! in black women involved in the sale and/or use of skin Idcaching creams.
